Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes.
OBJECTIVES To measure the effect of metformin on the body composition , insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus ( type 2 DM ) . DESIGN Placebo-controlled clinical trial . MATERIAL AND METHODS Twenty-three subjects with risk factors for type 2 DM were r and omly assigned to receive 850 mg of metformin or a placebo twice a day for 2 months . Before and after the treatment , the body mass index and waist/hip ratio were calculated , the body composition was measured through bioelectric impedance and the fasting levels of blood glucose , insulin , triglycerides and cholesterol were measured . The level of insulin resistance was calculated by the homeostatic model and the level of sensitivity by the quantitative insulin sensitivity check index method . The Wilcoxon rank test was used . RESULTS Twenty-one subjects completed the study , 12 of the metformin group and nine of the placebo group . In the metformin group , there was a decrease in fat weight from 25.9 + /- 9.4 to 20.8 + /- 9.2 kg , p < 0.01 , an increase in lean weight from 57.05 + /- 13.6 to 61.9 + /- 16.5 kg , p < 0.01 , an increase in basal metabolism from 1735 + /- 413 to 1878 + /- 505 calories/day , p < 0.05 and an increase in body water , p < 0.05 . There was no significant decrease in insulin resistance . In the placebo group , the blood glucose increased from 84.7 + /- 13 to 96.7 + /- 16 mg/dl , p < 0.05 . There were no significant modifications in lipids . CONCLUSIONS The administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .